Featured Clinical Trial:
Colorectal cancer (product/compound: FOLFIRI; Bevacizumab; CT-322)
ClinicAid Locations: Southern California – Fountain Valley, Riverside
Status: Enrollment closed.
Condition: Colorectal Cancer
Product Name/Compound: FOLFIRI; Bevacizumab; CT-322
Full Study Title: A Randomized, Double-Blind, Phase II Trial of CT-322 (BMS-844203) Plus Irinotecan, 5-FU and Leucovorin (FOLFIRI) Versus Bevacizumab Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer
Study Summary: To determine the efficacy of CT-322 comparative to bevacizumab, both in combination with irinotecan, 5-FU and leucovorin in the second-line treatment of subject with metastatic colorectal cancer
Eligible Participants:
Inclusion (Eligible):
- ECOG Performance Status (PS) ≤1
- Histologically or cytologically confirmed, metastatic colorectal cancer
- Measurable disease by RECIST guidelines
- Evidence of disease progression following first-line therapy with a fluoropyrimidine, oxaliplatin, and bevacizumab
Exclusion (Not Eligible):
- Known CNS metastases
- Excessive risk of bleeding (including use of therapeutic anticoagulation) and history of thrombotic or embolic cerebrovascular accident
- Uncontrolled hypertension
- Clinically significant cardiovascular disease
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months
- Serious non-healing wound, active peptic ulcer, non-healing bone fracture, or bleeding skin metastasis
Study Phase: Phase II (What are Phases?)
To receive information and updates for this trial:
Please contact us and mention the Trial ID below.
Trial ID (ClinicalTrials.gov): NCT00851045
<< Back to all ClinicAid clinical trials
